Research programme: human genomics - CHUQ/SignalGene

Drug Profile

Research programme: human genomics - CHUQ/SignalGene

Alternative Names: Breast cancer research programme - SignalGene/CHUQ; human genomics research programme - SignalGene/CHUQ; Osteoporosis research programme - Signal Gene/CHUQ

Latest Information Update: 02 Dec 2002

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Centre Hospitalier Universitaire de Quebec; SignalGene [CEASED]
  • Developer Centre Hospitalier Universitaire de Quebec
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer; Osteoporosis; Psoriasis

Most Recent Events

  • 15 May 2002 Discontinued - Preclinical for Breast cancer in Canada (unspecified route)
  • 15 May 2002 Discontinued - Preclinical for Osteoporosis in Canada (unspecified route)
  • 09 May 2002 Discontinued - Preclinical for Psoriasis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top